Angie Risley - Smith Nephew Non-Executive Independent Director
| SNN Stock | USD 23.84 0.17 0.71% |
Director
Ms. Angie Risley is NonExecutive Independent Director of the company effective 18 September 2017. She appointed Chair of the Remuneration Committee on 12 April 2018. Career and experience After graduating from Exeter University, and completing a 1year personnel management programme, Angie joined the United Biscuits graduate scheme. After working in various different HR roles she joined Pizza Hut Ltd as Human Resources Director, a joint venture between PepsiCo and Whitbread plc. After five years she joined Whitbread, becoming Executive Director on the plc board responsible for HR and Corporationrationrate Social Responsibility in 2004. Between 20072013 she was the Group HR Director for Lloyds Banking Group, joining J Sainsbury plc as Group HRD in January 2013. Over the years, Angie was a member of the Low Pay Commission and has held a number of NonExecutive Directorships with Biffa plc, Arriva and Serco Group plc, and now Smith Nephew. At Serco she was the Chair of the Remuneration Committee. Previously she has attended Remuneration Committees of Whitbread, Lloyds Banking Group, Arriva and attends Sainsburys today. She is also a NonExecutive Director on the Sainsburys Bank Board. Skills and competencies Angie is a wellregarded FTSE 100 Human Resources Director, proven NonExecutive Director and Remuneration Committee Chair. She has gained experience in a wide range of sectors, including a regulated environment. This diversity of experience is welcomed by the Board and the Remuneration Committee. Angie is also an additional resource and sounding board for Smith Nephews own internal Human Resources function. since 2017.
| Age | 62 |
| Tenure | 7 years |
| Address | Building 5, Watford, United Kingdom, WD18 8YE |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has Return on Asset of 0.0427 % which means that on every $100 spent on assets, it made $0.0427 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0502 %, implying that it generated $0.0502 on every 100 dollars invested. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to drop to 0.04. In addition to that, Return On Capital Employed is likely to drop to 0.12. At this time, Smith Nephew's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 6.3 B, while Other Current Assets are likely to drop about 87.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Robert Epstein | Illumina | 62 | |
| Jeffrey Huber | Illumina | 46 | |
| Sue Rataj | Agilent Technologies | 63 | |
| Virginia Wilson | Charles River Laboratories | 66 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Linda Baddour | Waters | 62 | |
| Martiny Harris | Thermo Fisher Scientific | 59 | |
| Edward Conard | Waters | 63 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Judy Lewent | Thermo Fisher Scientific | 71 | |
| Lars Sorensen | Thermo Fisher Scientific | 67 | |
| Heidi Fields | Agilent Technologies | 60 | |
| David Walt | Illumina | 62 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| Heidi Kunz | Agilent Technologies | 66 | |
| George Milne | Mettler Toledo International | 71 | |
| Caroline Dorsa | Illumina | 58 | |
| Paul Clark | Agilent Technologies | 72 | |
| Tadataka Yamada | Agilent Technologies | 74 | |
| Tyler Jacks | Thermo Fisher Scientific | 59 | |
| Richard Wallman | Charles River Laboratories | 69 | |
Management Performance
| Return On Equity | 0.0502 | ||||
| Return On Asset | 0.0427 |
Smith Nephew SNATS Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Friedman, Non-Executive Independent Director | ||
| Helen Barraclough, Company Counsel | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Chief Executive Officer, Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Independent Director | ||
| Simon Fraser, President - Advanced Wound Management and Global Commercial Operations | ||
| John Rogers, CFO Director | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, Chief Financial Officer, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Ian Melling, Interim Chief Financial Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, Senior Communications | ||
| Rick Medlock, Non-Executive Independent Director | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Paul Connolly, President Operations | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Independent Director | ||
| Mark Gladwell, President - Global Operations and Global Business Services | ||
| John Ma, Non-Executive Independent Director | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Namal Nawana, Chief Executive Officer, Executive Director | ||
| Bob White, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Independent Director | ||
| Deepak Nath, Chief Executive Officer | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Independent Director | ||
| AnneFrancoise Nesmes, Chief Financial Officer, Executive Director | ||
| Rodrigo Bianchi, Interim President - Asia Pacific | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, President Orthopaedics | ||
| Katarzyna MazurHofsaess, Non-Executive Independent Director | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Peter Coenen, President - EMEA Region | ||
| Robin Freestone, Senior Non-Executive Independent Director | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Myra Eskes, President - Asia Pacific | ||
| Andrew Swift, Vice Relations | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Steve Kane, Global US | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President - Sports Medicine & ENT | ||
| Jo Hallas, Non-Executive Director | ||
| Catheryn ORourke, Chief Legal and Compliance Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0502 | ||||
| Return On Asset | 0.0427 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 23.64 B | ||||
| Shares Outstanding | 437.17 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 7.57 % | ||||
| Number Of Shares Shorted | 1.98 M | ||||
| Price To Earning | 25.42 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
When determining whether Smith Nephew SNATS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Smith Nephew's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Smith Nephew Snats Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Smith Nephew Snats Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew SNATS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Smith Stock analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Smith Nephew's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Smith Nephew. If investors know Smith will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Smith Nephew listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.983 | Dividend Share 0.375 | Earnings Share 0.6 | Revenue Per Share 2.5484 | Quarterly Revenue Growth 0.076 |
The market value of Smith Nephew SNATS is measured differently than its book value, which is the value of Smith that is recorded on the company's balance sheet. Investors also form their own opinion of Smith Nephew's value that differs from its market value or its book value, called intrinsic value, which is Smith Nephew's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Smith Nephew's market value can be influenced by many factors that don't directly affect Smith Nephew's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Smith Nephew's value and its price as these two are different measures arrived at by different means. Investors typically determine if Smith Nephew is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Smith Nephew's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.